lacking substantial evidence of effectiveness is requested to submit a supplement to his application, as needed, to provide for revised labeling which deletes those indications for which substantial evidence of effectiveness is lacking and which contains an indications section in accord with that described below. Such supplement should be submitted under the provisions of § 130.9(d) and (e) of the new drug regulations (21 CFR 130.9(d) and (e)) which permits certain changes to be put into effect at the earliest possible time, and the revised labeling should be put into use within the 60-day period. Failure to do so may result in a proposal to withdraw approval of the new drug application.

2. If any such preparation is on the market without an approved new drug application, its labeling should be revised to delete all claims for which substantial evidence of effectiveness is lacking as described in paragraph A above and to be in accord with this notice. Failure to delete such indications and to put the revised labeling into use within 60 days after the date of publication of this notice hereof in the Federal Register may cause the drug to be subject to regulatory proceedings.

3. Labeling revised pursuant to this notice should take into account the comments of the Academy; furnish adequate information for safe and effective use of the drug; and recommend use of the drug (for the probably effective indications) as follows:

*INDICATIONS*

**PROTOTYPKOL HYDROCHLORIDE FOR INJECTION**

For the symptomatic relief of acute and chronic bronchial asthma; and for bronchospasm associated with emphysema, chronic bronchitis, and bronchiectasis.

**EPINEPHRINE SUSPENSION PARENTERAL**

For the symptomatic treatment of bronchial asthma; urticaria; angioedema; and hay fever.

4. The notice Conditions for Marketing New Drugs Evaluated in Drug Efficacy Study, published in the Federal Register July 14, 1970 (35 F.R. 11272), describes in paragraphs (c), (e), and (f) the marketing status of the drug labeled with those indications for which it is regarded as probably effective. For epinephrine suspension parenteral it is recommended that applicants discuss with the administration the kinds of clinical studies needed.

A copy of the Academy's report has been furnished to each firm referred to above. Communications forwarded in response to this announcement should be identified with the reference number DESI 366, directed to the attention of the appropriate office listed below, and addressed to the Food and Drug Administration, 550 Fishers Lane, Rockville, Md. 20852.

Supplements (Identify with NDA number):

- Office of Scientific Evaluation (BD-100), Bureau of Drugs.
- Bureau of Drugs.

Requests for the Academy's report: Drug Efficacy Study Information Control (BD-67), Bureau of Drugs.

All other communications regarding this announcement: Drug Efficacy Study Implementation Project Office (BD-80), Bureau of Drugs.

This notice is issued pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (secs. 502, 505, 52 Stat. 1050–53, as amended; 21 U.S.C. 352, 355) and under the authority delegated to the Commissioner of Food and Drugs (21 CFR 2.120).

Dated: June 28, 1972.

SAM D. FINE, Associate Commissioner for Compliance.

[FR Doc. 72–10534 Filed 7–10–72; 8:49 am]

**DESI 6403**

**CERTAIN PERIPHERAL VASODILATORS**

**Drugs for Human Use; Drug Efficacy Study Implementation**

The Food and Drug Administration has evaluated reports received from the National Academy of Sciences-National Research Council, Drug Efficacy Study Group, on the following peripheral vasodilation drugs:

1. Priscoline Hydrochloride Tablets and Injection, each containing tolazoline hydrochloride; Ciba Pharmaceutical Co., Division Ciba-Geigy Corp., 588 Morris Avenue, Summit, N.J. 07901 (NDA 4–603).

2. Priscoline Hydrochloride Lontabs, sustained release tablets containing tolazoline hydrochloride; Ciba Pharmaceutical Co. (NDA 11–770).

3. Vasodilan Injection and Tablets, each containing isoxsuprine hydrochloride; nylidrin hydrochloride; Ciba Pharmaceutical Co. (NDA 11–760).

4. All these drugs, tolazoline hydrochloride, isoxsuprine hydrochloride, nylidrin hydrochloride, phenoxybenzamine hydrochloride, and phenoxybenzamine hydrochloride, are regarded as possibly effective for their labeled indications other than those described above.

**Marketing status.** Within 60 days of the date of publication of this announcement in the Federal Register, the holder of any approved new drug application for a drug classified in paragraph A above as lacking substantial evidence of effectiveness is requested to submit a supplement to his application, as needed, to provide for revised labeling which deletes those indications for which substantial evidence of effectiveness is lacking. Such a supplement should be submitted under the provisions of § 130.9(d) and (e) of the new drug regulations (21 CFR 130.9(d) and (e)) which permit certain changes to be put into effect at the earliest possible time, and the revised labeling should be put into use within 60 days after the date of publication of this announcement hereof in the Federal Register. Failure to do so may result in a proposal to withdraw approval of the new drug application.

2. Nylindrin hydrochloride lacks substantial evidence of effectiveness for the treatment of cerebrovascular disorders such as cerebral arteriosclerosis; relief of pain, ache, spasm, intermittent claudication, paresthesias, numbness, coldness, increased walking ability, promotion of healing of trophic ulcers associated with livedo reticularis; all forms of peripheral vascular disease; and increasing the blood flow in the brain and eye, with clinical application in cerebral arteriosclerosis and other ischemic disturbances of the brain and eye.

3. Epinephrine hydrochloride lacks substantial evidence of effectiveness as a cerebral vasodilator in the management of hypertensive and arteriosclerotic cerebral vascular disease, as a uterine relaxant in the management of dysmenorrhoea and uterine spasm, for the symptomatic relief of vascular insufficiency associated with peripheral vascular disease, post-phlebitic conditions, acroparesthesia, frostbite syndrome, ulcers of the extremities, as a peripheral vasodilator in the management of diabetic arteriosclerosis, diabetic vascular disease, for arterial thromboembolic occlusion, and for use in premature labor.

4. All these drugs, tolazoline hydrochloride, isoxsuprine hydrochloride, nylidrin hydrochloride, phenoxybenzamine hydrochloride, and phenoxybenzamine hydrochloride, are regarded as possibly effective for their labeled indications other than those described above.

**Marketing status.** Within 60 days of the date of publication of this announcement in the Federal Register, the holder of any approved new drug application for a drug classified in paragraph A above as lacking substantial evidence of effectiveness is requested to submit a supplement to his application, as needed, to provide for revised labeling which deletes those indications for which substantial evidence of effectiveness is lacking. Such a supplement should be submitted under the provisions of § 130.9(d) and (e) of the new drug regulations (21 CFR 130.9(d) and (e)) which permit certain changes to be put into effect at the earliest possible time, and the revised labeling should be put into use within 60 days after the date of publication of this announcement hereof in the Federal Register. Failure to do so may result in a proposal to withdraw approval of the new drug application.

2. If any such preparation is on the market without an approved new drug application, its labeling should be revised if it includes those claims for which substantial evidence of effectiveness is lacking as described in paragraph A above. Failure to delete such indications and to put the revised labeling into use within 60 days after the date of publication of this announcement hereof in the Federal Register may cause the drug to be subject to regulatory proceedings.

3. The notice Conditions for Marketing New Drugs Evaluated in Drug Efficacy Study, published in the Federal Register July 14, 1970 (35 F.R. 11272), describes in paragraphs (d), (e), and (f) the marketing status of the drug labeled with those indications for which it is regarded as probably effective. For epinephrine suspension parenteral it is recommended that applicants discuss with the administration the kinds of clinical studies needed.

A copy of the Academy's report has been furnished to each firm referred to above. Communications forwarded in response to this announcement should be identified with the reference number DESI 366, directed to the attention of the appropriate office listed below, and addressed to the Food and Drug Administration, 550 Fishers Lane, Rockville, Md. 20852.

Supplements (Identify with NDA number):

- Office of Scientific Evaluation (BD-100), Bureau of Drugs.
- Bureau of Drugs.

Requests for the Academy's report: Drug Efficacy Study Information Control (BD-67), Bureau of Drugs.

All other communications regarding this announcement: Drug Efficacy Study Implementation Project Office (BD-80), Bureau of Drugs.

This notice is issued pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (secs. 502, 505, 52 Stat. 1050–53, as amended; 21 U.S.C. 352, 355) and under the authority delegated to the Commissioner of Food and Drugs (21 CFR 2.120).

Dated: June 28, 1972.

SAM D. FINE, Associate Commissioner for Compliance.

[FR Doc. 72–10534 Filed 7–10–72; 8:49 am]

**DESI 6403**

**CERTAIN PERIPHERAL VASODILATORS**

**Drugs for Human Use; Drug Efficacy Study Implementation**

The Food and Drug Administration has evaluated reports received from the National Academy of Sciences-National Research Council, Drug Efficacy Study Group, on the following peripheral vasodilation drugs:

1. Priscoline Hydrochloride Tablets and Injection, each containing tolazoline hydrochloride; Ciba Pharmaceutical Co., Division Ciba-Geigy Corp., 588 Morris Avenue, Summit, N.J. 07901 (NDA 4–603).

2. Priscoline Hydrochloride Lontabs, sustained release tablets containing tolazoline hydrochloride; Ciba Pharmaceutical Co. (NDA 11–770).

3. Vasodilan Injection and Tablets, each containing isoxsuprine hydrochloride; nylidrin hydrochloride; Ciba Pharmaceutical Co. (NDA 11–760).

4. All these drugs, tolazoline hydrochloride, isoxsuprine hydrochloride, nylidrin hydrochloride, phenoxybenzamine hydrochloride, and phenoxybenzamine hydrochloride, are regarded as possibly effective for their labeled indications other than those described above.

**Marketing status.** Within 60 days of the date of publication of this announcement in the Federal Register, the holder of any approved new drug application for a drug classified in paragraph A above as lacking substantial evidence of effectiveness is requested to submit a supplement to his application, as needed, to provide for revised labeling which deletes those indications for which substantial evidence of effectiveness is lacking. Such a supplement should be submitted under the provisions of § 130.9(d) and (e) of the new drug regulations (21 CFR 130.9(d) and (e)) which permit certain changes to be put into effect at the earliest possible time, and the revised labeling should be put into use within 60 days after the date of publication of this announcement hereof in the Federal Register. Failure to do so may result in a proposal to withdraw approval of the new drug application.

2. If any such preparation is on the market without an approved new drug application, its labeling should be revised if it includes those claims for which substantial evidence of effectiveness is lacking as described in paragraph A above. Failure to delete such indications and to put the revised labeling into use within 60 days after the date of publication of this announcement hereof in the Federal Register may cause the drug to be subject to regulatory proceedings.

3. The notice Conditions for Marketing New Drugs Evaluated in Drug Efficacy Study, published in the Federal Register July 14, 1970 (35 F.R. 11272), describes in paragraphs (d), (e), and
NOTICES

DESI 6403, directed to the attention of labeled with those indications for which the appropriate office listed below, and identified with the reference number above. Communications forwarded in 13566 Commissioner of Food and Drugs (21 and under the authority delegated to the Fifth Street, Bristol, Tenn. 37620 (NDA triasilicate; The S. E. Massengill Co., 527 aluminum hydroxide gel and magnesium sone, calcium pantothenate, dried aluminum hydroxide gel; Merck Sharp & Dohme (NDA 10-372).

Deltacortril-APC Tablets containing prednisolone, aspirin, phenacetin and caffeine; Chas. Pfizer and Co., Inc. (NDA 10-774).

C. Methyldprednisolone in combination with other active components. 1. Medapsin Tablets and MedaMental Tablets containing prednisolone, hydrochloride, aspirin and calcium carbonate (NDA 11-852); and

2. Cordex Improved Tablets and Cordex-Forte Improved Tablets containing methylprednisolone and aspirin (NDA 11-455); The Upjohn Co.

D. Dexamethasone in combination with other active components. 1. Deca- gesic Tablets containing dexamethasone, aspirin and dried aluminum hydroxide gel; Merck Sharp & Dohme (NDA 12-187).

2. Delenar Tablets containing dexamethasone, orphenadrine hydrochloride and aluminum aspirin; Schering Corp., 1011 Morris Ave, Union, N.J. 07083 (NDA 12-992).

3. Dronactin Tablets containing dexamethasone and cyproheptadine hydrochloride, Merck Sharp & Dohme (NDA 13-084).

E. Cortisone acetate in combination with other active components. 1. Salcort Tablets containing cortisone acetate, sodium salicylate, dried aluminum hydroxide gel, calcium ascorbate and calcium carbonate; The S. E. Massengill Co. (NDA 9-414).

2. Prodecem Tablets containing prednisone, calcium pantothenate, dried aluminum hydroxide gel and magnesium trisilicate; The S.E. Massengill Co., 597 Fifth Street, Bristol, Tenn. 37620 (NDA 11-022).

3. Prednisolone in combination with other active components. 1. Alaspad Tablets containing 2.5 mg. or 5.0 mg. prednisone, magnesium trisilicate and dried aluminum hydroxide gel; Merck, Sharp, & Dohme, Division Merck and Co., Inc., West Point, Pa. 19486 (NDA 10-371).

2. Predsem Tablets containing predni- sone, calcium pantothenate, dried aluminum hydroxide gel and magnesium trisilicate; The S.E. Massengill Co., 597 Fifth Street, Bristol, Tenn. 37620 (NDA 11-022).

3. Prednisolone in combination with other active components. 1. Alaspad Tablets containing 2.5 mg. or 5.0 mg. prednisolone and hydroxyde hydrochloride; Chas. Pfizer and Co., Inc., 235 East 42d Street, New York, N.Y. 10017 (NDA 10-639).

2. Cordex Tablets and Cordex-Porte Tablets containing prednisolone and aspirin (NDA 10-639).

3. Cordex (Buffered) Tablets and Cordex-Porte (Buffered) Tablets containing prednisolone, aspirin and calcium carbonate (NDA 10-188); The Upjohn Co., 7171 Fortage Road, Kalamazoo, Mich. 49002.

4. Co-Hydril Tablets containing 2.5 mg. or 5.0 mg. prednisolone, magnesium trisilicate and dried aluminum hydroxide gel; Merck Sharp & Dohme (NDA 10-372).

5. Deltacortril-APC Tablets containing prednisolone, aspirin, phenacetin and caffeine; Chas. Pfizer and Co., Inc. (NDA 10-774).

Prior to initiating such action, however, the Commissioner invites the holders of the new-drug applications for these drugs and any interested persons who might be adversely affected by the removal of the market, to submit pertinent data bearing on the proposition within 30 days after publication in the Federal Register. To be acceptable for consideration in support of the effectiveness of a drug, any such data must be previously unsubmitted, well organized, and include data from adequate and well controlled clinical investigations (identified for review) as described in section 130.12(a) (5) of the regulations published as a final order in the Federal Register of May 8, 1970 (35 F.R. 7250). Carefully conducted and documented clinical studies obtained under uncontrolled or partially controlled situations are not acceptable as a sole basis for the approval of claims of effectiveness, but such studies may be considered on their merits for corroborative support of efficacy and evidence of safety.

A copy of the Academy's report has been furnished to each firm referred to above. Communications forwarded in response to this announcement should be identified with the reference number DESI 9414, directed to the attention of the appropriate office listed below, and addressed to the Food and Drug Administration, 5600 Fishers Lane, Rockville, Md. 20852.

Requests for the Academy's report: Drug Efficacy Study Information Control (BD-67), Bureau of Drugs.

All other communications regarding this announcement should be addressed to the Food and Drug Administration, 5600 Fishers Lane, Rockville, Maryland 20852.

Dated: June 28, 1972.

SAM D. FINE, Associate Commissioner for Compliance.

FEDERAL REGISTER, VOL. 37, NO. 133-TUESDAY, JULY 11, 1972

NOTICES

CERTAIN STEROID COMBINATION PREPARATIONS FOR ORAL USE

Drugs for Human Use; Drug Efficacy Study Implementation

The Food and Drug Administration has evaluated reports received from the National Academy of Sciences-National Research Council, Drug Efficacy Study Group, on the following drugs:

A. Prednison in combination with other active components. 1. Co-Delta Tablets containing 2.5 mg. or 5.0 mg. prednisone, magnesium trisilicate and dried aluminum hydroxide gel; Merck, Sharp, & Dohme, Division Merck and Co., Inc., West Point, Pa. 19486 (NDA 10-371).

2. Predsem Tablets containing prednisone, calcium pantothenate, dried aluminum hydroxide gel and magnesium trisilicate; The S.E. Massengill Co., 597 Fifth Street, Bristol, Tenn. 37620 (NDA 11-022).

B. Prednisolone in combination with other active components. 1. Alaspad Tablets containing 2.5 mg. or 5.0 mg. prednisolone and hydroxyde hydrochloride; Chas. Pfizer and Co., Inc., 235 East 42d Street, New York, N.Y. 10017 (NDA 10-639).

2. Cordex Tablets and Cordex-Porte Tablets containing prednisolone and aspirin (NDA 10-639).

3. Cordex (Buffered) Tablets and Cordex-Porte (Buffered) Tablets containing predni-